Fosun set for $500m-plus deal for early stage compounds
This article was originally published in Scrip
In a reversal of prevailing deal flow over the past few months, during which a number of Chinese pharma firms have licensed in projects and technology from Western partners, a small Swiss company is preparing to acquire two drug candidates from China's Fosun group.
You may also be interested in...
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.